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Introduction
Visceral Leishmaniasis (VL) or kala-azar is a zoonotic disease 
caused by Leishmaniainfantum, in the Mediterranean area, and by 
Leishmania chagasi in Latin America and China [1]. It is endemic in 
less developed countries; however, incidences are increasing in non-
endemic areas due to changing patterns of international travel and to 
population migration [2]. VL currently affects 12 million individuals 
and it is an opportunistic infection in immunocompromised patients 
[3].
Dogs are the main reservoir of Leishmaniainfantum parasites, 
and they play a central role in the transmission to humans through 
phlebotomine sandflies [4,5]. A large amount of evidence has 
demonstrated that the prevalence and incidence of canine Leishmaniasis 
(CanL) has, until now, been underestimated [6,7]. In addition to dogs, 
wild canids, such as jackals (Canis aureus) and red fox (Vulpes vulpes), 
are potential feral reservoirs for Leishmania infantum [8].
After infection, some dogs can control the parasite and don’t 
develop the disease in the short term, sometimes remaining subclinical 
for years or for their entire lifetime, whereas others may present 
progressive disease [9]. The presence of latent infection in dogs is 
typical and contributes to maintaining the long-term presence of the 
parasite in endemic regions. Disease management represents a serious 
problem since both symptomatic and asymptomatic dogs are infective 
to phlebotomine vectors [10], and the available antileishmanial drugs 
have limited efficacy in dogs [11,12].
The data currently available for canine VL show that the clinical 
appearance and evolution of Leishmaniasis is a consequence of 
complex interactions between the parasite and host immune response. 
The outcome of infection depends on the ability of host macrophages 
to effectively destroy the parasite. This activity is determined by the 
balance between a heterogeneous set of cytokines [13]. Previous 
studies on the immune responses in experimentally infected dogs, have 
revealed that T lymphocytes and the cytokines play a crucial role in 
determining whether infection evolves toward a protective immunity 
status or a progressive and manifested disease [14].
Two different T helper (Th) cell subsets, termed Th1 and Th2, 
which differ from each other in the profile of secreted cytokines, have 
been described [15]. In the murine model for Leishmaniasis, the Th1 
response confers protection, whereas the Th2 response renders the host 
susceptible to infection [16-18]. Studies on the immune response in 
dogs experimentally infected with Leishmania infantum have shown 
that the protective immunity is associated with the production of IL-
2, IFN-γ and TNF-α by peripheral blood mononuclear cells (PBMC) 
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Abstract
Background: Visceral Leishmaniasis (VL) is a zoonotic disease caused by Leishmaniainfantum in the 
Mediterranean area. Dogs are the main reservoir of Leishmaniainf antum parasites. Disease management represents 
a serious problem, since anti-Leishmania drugs have limited efficacy in both symptomatic and asymptomatic dogs, 
which are infective to phlebotomine vectors. In many tropical and sub-tropical countries the development of a safe 
and easily-available vaccine has high priority. DNA vaccines represent one of the most recent innovations in the field 
of immunization.
Findings: This study aimed to evaluate the effect of a DNA vaccine based on two Leishmania antigens (Cpb1, 
PO) in leishmaniotic dogs. Twelve leishmaniotic dogs from a Leishmaniasis-endemic area (Naples, Italy) received 
three consecutive injections of DNA vaccine at 15-days intervals. Another group of five leishmaniotic dogs received 
the same amount of pVAX-1 without the coding sequences of Leishmania antigens. Leishmania DNA load, INFγ, 
IL-4 mRNA expression levels and clinical parameters were tested before and after the therapy, every 3 months for 
a period of 12 months. 
Analysis of the data in the vaccinated dogs showed: i) a decrease Leishmania DNA load in lymph node samples, 
ii) an increase of INFγ and IL-4 mRNA expression levels in PBMC samples. All vaccinated dogs also showed an 
improvement in the clinical symptoms. 
Conclusion: Our results show that the vaccine developed in this study may represent a useful tool in the 
treatment of leishmaniotic dogs. However, since the duration of positive effects is limited in time, further trials are 
needed to evaluate the effectiveness of immunotherapy alone or in association with conventional therapy. 
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in addition to the induction of parasite-specific cytotoxic T cells [9]. 
Furthermore, the activation of macrophages by IFN-γ has been shown 
to result in nitric oxide production which mediates the killing of 
intracellular parasites [19, 20]. On the other hand development of the 
disease is associated with the production of other interleukins such as 
IL 10, IL 12, IL 18 etc.
In the last decade, the polymerase chain reaction (PCR) has been 
successfully introduced and proven to be a sensitive and powerful 
tool to detect Leishmania in clinical samples as well as for parasite 
characterization [21-23]. Very recently, PCR has also been used to 
analyse the immune response profile either in humans or in infected 
dogs [24]. However, the multiple steps of post-PCR manipulation 
require time and pose the risk of DNA contamination. A recent approach 
to estimating the parasitic load of mouse livers experimentally infected 
with Leishmania infantum has been based on the use of a double real-
time quantitative PCR test targeting the parasite DNA polymerase 
gene and the mouse brain-derived neutrophic factor gene [25,26]. 
Furthermore, a real-time PCR that simultaneously detects, quantitates 
and differentiates Leishmania organisms has been developed [27,28]. 
Control of Leishmaniasis currently includes the use of combined 
chemotherapeutic treatments and vector control by the use of insect 
repellent. Stamping out is a widely used practice in countries such as 
Brazil, however attempts to remove seropositive dogs has proven to be 
insufficient for eradicating visceral Leishmaniasis in dogs [29] . 
It is generally accepted that an effective vaccine against canine 
Leishmaniasis is the best strategy for disease control. Among vaccine 
type, the DNA vaccine seems to be the most promising due to their 
ability to efficiently stimulate both humoral and cellular immune 
immunity in many infectious disease models [30]. 
A DNA vaccine typically consists of a foreign gene, encoding a 
protein antigen of interest, cloned into a bacterial plasmid under the 
control of an appropriate promoter that can be injected into the skin 
or muscle of the the host. After uptake of the plasmid, the protein is 
produced endogenously and intracellularly and the antigenic peptides 
can be presented on the cell surface in the context of both the MHC 
class I and MHC class II pathway [31].
In this study, a new DNA vaccine, which expresses both Cysteine 
proteinases b1 (CPb1) and acidic ribosomal protein PO (LiPO) of 
Leishmania infantum was constructed.
The immunotherapeutic potential of this vaccine was assessed in 12 
naturally infected dogs.
The quantitative real-time PCR (qPCR) assay was used for 
measuring: a) Leishmania DNA load in lymph node aspirates; b) the 
expression levels of cytokines relative to either Th1 or Th2 patterns.
Both parasite DNA load and cytokine expression levels were also 
evaluated in a group of healthy uninfected dogs used as the control 
group.
Materials and Methods
Plasmid construction and purification
The coding sequences of two Leishmania antigens Cpb1 and PO 
were inserted into the pVAX-1 vector to obtain the pVAX/Cpb1/
Po plasmid. pVax CPB1/PO encodesthe full-length sequences of 
the Cpb1 and PO genesplaced downstream of the cytomegalovirus 
(CMV) promoter and upstream of the bovine growth hormone (BGH) 
polyadenylation sequence in the pVax1ΤΜ vector (Invitrogen). The 
sequences of the Cpb1 and POgenes were derived from GenBank 
(accession number AJ628942.1 and X72714.1 respectively) and were 
synthesized by GenScript, USA Inc. in a concatameric formation with 
a linking sequence of repeats coding for a serine/glycine rich peptide 
flexible bridge rotating on a threonine hinge, as described previously 
(Robinson and Sauer, 1998). The pVax CPB1/PO plasmid was used 
for the invitro experiments and clinical vaccine trials described below. 
The plasmid pUC CPB1/PO encodes the Cpb1/PO fused genes cloned 
in the multiple cloning sites (MCS) of the pUC19 cloning vector and 
was used as negative control for in vitro experiments. Plasmid DNA for 
vaccine clinical trials was purified with the Endo Free Plasmid Giga Kit 
(Qiagen) using endotoxin-free material and eluted in endotoxin-free 
deionised water.
Expression of Cpb1/PO genes in transfected cells
The human embryonic kidney cell line HEK 293 was transfected 
with pVax CPB1/PO and with the negative controls pUC/Cpb1/PO, 
using the CalPhos Mammalian Transfection Kit (Clontech), according 
to the manufacturer’s instructions. Transfected cells were harvested 48 
h later and washed with phosphate-buffered saline three times. Total 
RNA was extracted with Trizol reagent (Invitrogen) and treated with 
DNaseI (Invitrogen). Complementary DNA (cDNA) was obtained 
from RNA with the SuperScriptTM First-Strand Synthesis System 
(Invitrogen). CPB1/PO cDNA was amplified by PCR. The amplified 
products were analyzed with a 1% agarose gel. Robustness of plasmids 
expressing CPB1/PO was evaluated by replicating the expression 
experiments three times.
Also, production of Cpb1/PO protein was detected by 
immunoblotting (B) using an antiserum leishmaniotic dog Vaccine 
clinical trial.
This study included 12 dogs, hospitalized at the Department of 
Clinical Veterinary Sciences of the University of Naples, naturally 
infected by Leishmaniainfantum. These dogs were living in the endemic 
area of Campania Region in South Italy and included different breeds, 
ranged in age from 1 to 10 years. All dogs were diagnosed as having 
CanL on the basis of clinical manifestations, immunofluorescence 
antibodies IFAT, and qPCR tests.
Criteria for inclusion in this study were: Clinical findings 
compatible with Leishmaniasis (weight loss, peripheral 
lymphadenopathy, skin lesions, ocular lesions, epistaxis, lameness, 
ulcers, diarrhea and moderate glomerulopathy), alterations of 
ematobiochemical parameters compatible with Leishmaniasis 
(thrombocytopenia, anaemia, leukopenia; total proteins and beta 
globulins higher than normal value), presence of anti-Leishmania 
antibody with titres above 1:80, and a Leishmania DNA load in lymph 
node aspirate ranging from 100 parasites/ml.
Animals were scored for clinical and laboratory parameters on a 
scale from 0 to 9 and the values were added up to give a clinical score 
[32].
Vaccination protocol
At the time of diagnosis, 12 dogs which were treated 
contemporaneously with three intramuscular doses and three 
subcutaneous doses of 500 µg of plasmid, Pvax Po\CPB1 plasmid on 
days 0, 15, 30. 
Another group of five leishmaniotic dogs received the same amount 
of pVAX-1 without the coding sequences of Leishmania antigens 
(control group). These dogs were kept without treatment until there has 
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been a worsening of clinical symptoms, then, 6 months after the start of 
the study, they were subjected to specific treatment.
The efficacy of the therapy was evaluated at 0, 15 and 30 days 
from the beginning of the therapy, and 3, 6 and 12 months from the 
beginning of the therapy.
All dogs were given a clinical score on the basis of the presence 
and severity of clinical manifestations, the alterations of laboratory 
parameters, and the IFAT titre. In addition the Leishmania DNA load 
in the lymph node aspirates and mRNA expression levels of INF γ and 
IL4 in the blood were also measured at these times.
The Ethics Committee gave a positive opinion for treatment for 
compassionate use of dogs studied.
Sampling 
Whole blood samples were collected from the dogs in EDTA-
containing tubes by cephalic venipuncture. Lymph node aspirates were 
obtained by using a thin biopsy needle. Samples were stored at –80°C.
DNA extraction from tissue samples and from parasite cultures and 
RNA isolation and production of cDNAs were carried out as previously 
described [33].
Selection of primers and probes 
All TaqMan primers and probes were selected as previously 
reported [33]. All primers and FAM probes were provided from 
Applied Biosystems.
Real-time PCRanalysis 
Real-time PCR was performed as previously described [34,35].
Statistical analysis
Statistical analysis was carried out with GraphPad InStat software 3.0 
application. The significance of differences between the two groups was 
evaluated by using the Anova tests. All conclusions were based on significance 
levels of  p <0.05. Boxplot of results were generated by using the same software.
Results
Plasmid Pvax/Cpb1/PO was designed in order to investigate 
the immunotherapeutic potential of DNA vaccines against canine 
Leishmaniasis. To provide an enhanced immunological response, 
the proteins were linked together with a sequence encoding a glycine 
bridge. DNA sequencing confirmed the correct synthesis of Cpb1/
PO in Pvax1. To ensured that Cpb1/PO fusion proteins could indeed 
be transcribed in mammalian cells, the presence of specific mRNA 
was established by RT-PCR from total RNA isolated from HEK 293 
cells transfected with Pvax/Cpb1/PO plasmid. As shown in Figure 
1, an amplicon of approximately 1330 bp and 900 bp corresponding 
to Cpb1 and PO respectively was obtained from transfected cells 
(Figure 1A). Immunoblotting performed on HEK 293 cell lysates 
confirmed the presence of correct transcription of fusion protein 
Cpb1/PO (Figure 1B).
Before immunotherapy began, vaccinated dogs (Group1) had a 
mean clinical score of 7, while control dogs had a mean value of 5. Three 
months after the start of therapy, vaccinated dogs showed a progressive 
improvement in their clinical manifestations, as demonstrated by the 
decrease in their clinical scores (Figure 2). In addition the average 
clinical score was lower than before starting therapy. This decrease 
continued until 6 months after the beginning of therapy. At this 
point the average of clinical score of the vaccinated dogs started to 
progressively increase, and finally three dogs had a relapse.
The average of value of clinical score for the control group 
progressively increased from the beginning of the therapy to the end 
(Figure 2).
30 days after the start of the immunotherapy, vaccinated dogs 
showed a relevant decrease of Leishmania DNA that continues until 
3 months after the beginning of therapy. From this time point the 
Leishmania DNA load started to progressively increase without 
reaching original load. On the contrary the control group shows a 
progressive increase of DNA Leishmania load (Figure 3).
The IFN-γ and IL-4 mRNA expression levels in group 1 and in the 
control group were monitored by real time PCR (Figure 4).
IFN-γ mRNA levels of vaccinated dogs show a significant 


















Figure 1: Transcription of Cpb1/PO (A) and Cpb1/PO protein expression 
(B) as detected by RT-PCR and immunoblotting in transfected HEK 293 
cells. Cells were transfected with pVax/Cpb1/PO expression plasmids and 
with the negative controls pUC/Cpb1/PO (Mock) as described in materials 
and methods. Production of specific mRNA (A) was assessed 48 h later 
in transfected cells. Total RNA was purified from transfected cells and 
amplified by RT-PCR with specific primers. Cpb1/PO protein was detected by 
immunoblotting (B) using an antiserum from Leishmania positive dog, only in 

































Figure 2: Evaluation of clinical score during immunotherapy. Black columns 
represent the vaccinated group (12 dogs) while squared columns represent 
control group (5 dogs).
Both groups were injected at T0, 15 days and 30 days and at each time 
point dogs were clinically assessed for clinical score up to twelve month after 
first inoculation. The decrease of clinical score values was observed only in 
vaccinated groups whereas the control group shown a slight increase. Error 
bars indicate standard deviation (SD).
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in IL-4 mRNA levels where observed between the vaccinated and 
the control group. 
Discussion and Conclusions
DNA vaccination has been demonstrated to induce both humoral 
and cellular immune responses. Th1 cells can activate macrophages 
to destroy intracellular microorganisms and also activate B cells to 
produce strongly opsonizing antibodies such as IgG2a and IgG2b [31].
In this study, a pVAX based plasmid expressing the Cpb1 and PO 
proteins of Leishmaniainfantum was designed and evaluated in dogs 
diagnosed with symptomatic Leishmaniasis. As shown in Figure 1, 
Cpb1/PO mRNA was observed in transfected HEK 293 cells, and the 
Cpb1/PO fusion protein was detected by Western blotting analysis. 
Cpb1 and PO may represent an ideal candidate for the development 
of a DNA vaccine against Leishmaniainfection. Cysteine proteinases 
(CPs) are enzymes that belong to the papain superfamily, which 
are found in a number of organisms from prokaryotes to mammals. 
Previous data indicates that the Cysteine proteinases (CPA and CPB) 
inoculated as recombinant protein or as DNA vaccines is able to elicit a 
protective immune response against L. major in the murine model [36-
38]. Analysis of the immune response showed that vaccinated animals 
developed a specific Th1 immune response, which was associated with 
an increase of IFN-gamma production. PO is an acidic ribosomal 
protein. Administration of the P0 antigen from Leishmaniainfantum, 
either as soluble recombinant or as a plasmid DNA formulation confers 
protective immunity to Leishmania major infection in BALB/c mice [39].
The protective immunity against Leishmania is believed to be due 
to the action of the subpopulation of lymphocytes T helper type 1 [40]. 
The T lymphocyte activation determines proliferation, differentiation 
and production of cytokines such as IL-12, IFN-γ and TNF-α [41]. 
In presence of TNF activated macrophages produce NO which is 
considered the main mechanisms for Leishmania elimination [42].
Results in this study demonstrate that vaccination with pVAX/
Cpb1/PO determines a clinical improvement since 15 day after the 
first inoculation along with a decrease of DNA parasite load in the 
lymphnode. Improvement of clinical score and decrease of parasite 
burden progresses until 30 days post inoculation and stabilizes until 3 
months time point.
The clinical improvement is probably due to a decrease of organ 
parasitism. The remarkable decrease in parasite burden is a consequence 
of activation of effective immunity response. The outcome of infection 
by Leishmania depends on the balance between host ability to induce 
immune mechanisms against Leishmania and the parasite strategies 
to interfere in the process of antigen presentation and thus modulate 
the immune response mediated by T lymphocytes [43]. Expansion in 
the number of CD4 + T lymphocytes subset has been correlated to a 
reduction in organs parasitism in dogs undergoing immunotherapy 
and in vaccinated animals [44,45].
Previous studies analyzing peripheral blood lymphocyte correlates 
protective immune response against Leishmania infantum with CD4+ 
Th1 cells expressing IFN-γ, IL-2 e TNF-α. Cytokine patterns (IL-4) 
of CD4+ Th2 subset has been correlated to symptomatic state of the 
disease [46].
In our study, at 15 days and 30 days time points there is a 
significant increase of IFN-Γ mRNA levels, coinciding with the lowest 
DNA parasite load and lowest clinical score in vaccinated dogs. IL-4 
mRNA levels selected as Th2 response marker do not show significant 
variations along the clinical trial. Results suggest that pVAX/Cpb1/PO 
trigger an effective Th1 immune response. These effects are transient 
and more or less around the thirty months after the first inoculation we 
assist a progressive decline of the clinical status.
In conclusion, our results show that the vaccine developed in this 
study may represent a useful tool in the treatment of leishmaniotic 
dogs. However, further trials are needed to evaluate the effectiveness 



































Figure 3: Evaluation of parasite load during immunotherapy. Squares 
represent vaccinated group (12 dogs) while circles indicates control group 
(5 dogs). Fine-needle biopsy were taken and Leishmania DNA copies was 
estimated by qPCR at each time point. The axis indicates the number of 
Leishmania/ml expressed in logarithmic values.
In contrast to control group the vaccinated group exhibits a reduction of 






































































Figure 4:  Transcriptional analysis of PBMC cytokines mRNA expression 
levels during immunotherapy.
Cytokine mRNA levels in PBMC shows no relevant differences between the 
vaccinated and control group with the exception of the 15 days and the 30 
days time point of vaccinated group that shows a significant increase of IFN-γ. 
Error bars indicates standard deviation (SD).
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